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Active surveillance is becoming a more widely accepted management strategy in men 
with low-risk localized prostate cancer. This is in recognition of the knowledge that most 
men with such cancer are likely to die from other causes. The obvious benefits of active 
surveillance are reduced morbidity by delaying or avoiding radical gland therapy. 
These advantages should be balanced against appropriate selection criteria and trig-
gers for moving to radical therapy while on active surveillance. The optimal method 
by which to identify the small number of men who will progress by use of clinical, biopsy, 
and imaging data is yet to be defined. Nevertheless, active surveillance is an appealing 
management option in selected men with prostate cancer and represents a solution to 
the significant problem of the overdiagnosis of clinically insignificant disease that ac-
companies prostate-specific antigen (PSA) screening.
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INTRODUCTION
Active surveillance (AS), since first being described in 
2002, is now an accepted treatment strategy for men with 
low-risk prostate cancer (PCa) who previously received 
radical whole-gland treatment (surgery, external-beam 
radiation, or brachytherapy) [1]. The concept of AS evolved 
from watchful waiting, which meant no treatment until pro-
gression to metastatic or locally advanced disease, followed 
by androgen ablation therapy [2]. The concept is to cure 
clinically significant PCa rather than to wait for the devel-
opment of metastatic disease. For low-risk PCa, AS and 
radical treatment both have merits and disadvantages. AS 
has minimal morbidity with the inherent risk of pro-
gression associated with expectant management; radical 
therapies have an impact on erectile function and con-
tinence but provide definitive treatment [3,4]. Somewhere 
between AS and radical treatment lies focal therapy. Focal 
therapy has been limited to small cohorts with no extensive 
follow-up and cannot be recommended outside study proto-
cols [5]. The impact of focal therapy on the natural history 
of favorable-risk disease remains uncertain. Most men 
with favorable-risk PCa and their physicians will choose 
between AS and radical therapy. 
　In this review, we will focus on the rationale, patient se-
lection, method of follow-up, triggers for intervention, and 
recent results of this approach. 
RATIONALE AND ADVANTAGES OF ACTIVE 
SURVEILLANCE
AS for favorable-risk PCa has emerged as a credible man-
agement strategy within populations in which PCa screen-
ing is widespread. This is due to the observation that PCa 
screening by use of digital rectal exam (DRE), prostate-spe-
cific antigen (PSA), and biopsy results in the detection of 
disease that is not clinically significant in many patients 
(i.e., untreated, the cancer would not pose a threat to health 
or cause death). Furthermore, by treating men with favor-
able-risk PCa, we risk morbidity and even mortality when 
the disease, due to its long natural history, may never have 
been destined to have any clinical manifestations during Korean J Urol 2010;51:665-670
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TABLE 1. Selection criteria for active surveillance based on different protocols currently used worldwide
Variable
Klotz et al [18], 
(Original series from Toronto)
b Carter et al [19,20] van den Bergh et al [14] Kakehi et al [21]
Clinical stage T1c/T2a T1c T1c/T2 T1c
c
PSA level, ng/ml ≤10.0 - ≤10.0 ≤20.0
Biopsy Gleason score ≤3＋3=6 ≤3＋3=6 ≤3＋3=6 ≤3＋3=6
PSA density, ng/ml/ml - ≤0.15 ＜0.2 -
No. of positive cores - 2
a 22
a
PSA: prostate-specific antigen, 
a: and ＜50% of cancer in any core, 
b: for patients over age 70, these criteria were relaxed to include 
Gleason ≥7 (3＋4) and/or ≤PSA 15 ng/ml, 
c: age 50-80 years
the patient’s lifetime. Hence, AS is a solution to the widely 
acknowledged problems of overdiagnosis and overtreat-
ment of clinically insignificant disease that accompany the 
early detection of PCa [6].
　AS is flexible in that it allows for initial assessment of 
disease prior to deciding on it as a course of management. 
This is possible by incorporating a period of initial ob-
servation into patient management with the belief that if 
appropriate triggers for intervention are followed, then the 
patient will still have a favorable outcome when under-
going radical therapy. This approach helps to manage the 
subset of patients with initially apparent favorable-risk 
PCa who actually are at risk, due to either higher risk dis-
ease undetected at diagnosis or progression to a more ag-
gressive phenotype of PCa over the period of surveillance. 
AS relies on defined triggers to detect and predict higher 
risk disease while on such a program. Tools used in the pub-
lished surveillance series include serial PSAs, DREs, and 
repeat prostate biopsies. Magnetic resonance imaging 
(MRI) and biomarkers have an emerging role. These will 
be discussed later in greater detail.
　The approach of AS has been summarized as that which 
(1) identifies patients who have a low likelihood of disease 
progression during their lifetime on the basis of clinical and 
pathologic features of the disease and patient age and 
co-morbidity, (2) includes adherence to close monitoring 
over time, (3) includes reasonable criteria or triggers for in-
tervention that will both identify more aggressive disease 
in a timely fashion and also not result in excessive treat-
ment, and (4) improves communication to reduce the psy-
chological burden of living with an untreated cancer [6].
POTENTIAL DISADVANTAGES OF ACTIVE 
SURVEILLANCE
The obvious disadvantage of AS where selective delayed 
therapy is relied upon is that the “window of opportunity” 
for cure may be missed. Individual risk of disease pro-
gression is difficult to assign, so of concern is a small but 
real possibility of progression to death in the AS population 
because of the loss of opportunity for cure during the sur-
veillance period. PCa has an exceptionally long natural his-
tory, characterized typically by initiation in the 30s, clin-
ical diagnosis in the 50-60s, and death from disease in the 
80s. This represents a 50-year time course. Thus, most be-
lieve that a treatment delay of 1 or 2 years in patients who 
are reclassified as higher risk and then treated is unlikely 
to significantly alter cancer mortality. Further, although 
AS may appear to have little morbidity, several studies 
have shown a deterioration of quality of life (QoL) and sex-
ual function [7-11]. Alternatively, QoL is likely to deterio-
rate if all men with low-risk disease are offered radical 
treatments with the known impacts on sexual function and 
continence, the very reasons AS was established as a 
strategy.
　Finally, a small attrition rate can be expected because 
of men who are unable or unwilling to tolerate surveillance. 
This must be accepted from the outset for any individual 
[12].
UPTAKE OF ACTIVE SURVEILLANCE
Although AS has gained popularity, it is still infrequently 
utilized in some regions. Patients and/or their physicians 
appear to want to treat the PCa once diagnosed. For example, 
in the United States, only approximately 10% of eligible men 
are put on AS protocols [13], and even in countries where 
AS is largely accepted as a treatment strategy, only 30% 
of eligible men are on AS [14]. It must be noted that the dis-
cussion and acceptance of AS in guidelines and recom-
mendations by learned bodies has been far greater [15,16]. 
SELECTION CRITERIA FOR ACTIVE 
SURVEILLANCE
A genuine concern is that patients thought to have clin-
ically insignificant PCa might actually harbor cancer with 
unfavorable pathological features [17]. However, in any in-
dividual patient, it may be difficult to perfectly differ-
entiate between clinically insignificant and life-threat-
ening PCa [16]. This requires the selection for AS patients 
to be stringent. Prospective studies outlining the ideal se-
lection married with adequate follow-up and intervention 
data are lacking. No randomized trials comparing selection 
criteria exist, and data are likely to be obtained from larger 
prospective cohorts. At present, an array of selection cri-
teria to define favorable cases or even low-risk or clinically 
insignificant cancer confronts a urologist [14,18-21] (Table Korean J Urol 2010;51:665-670
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1). Most of the data for selecting patients work backward 
from the concept of an insignificant tumor found at radical 
prostatectomy, which in itself may be a flawed concept. 
This is because given the different theories regarding the 
relevance of PCa as multifocal disease and the idea of a 
dominant or index lesion being responsible for progression 
or metastases, prospective data are likely to be more en-
lightening, but are not yet available. 
　Outcomes in men outside the more accepted selection cri-
teria (e.g., Gleason score of 6) for AS are lacking. In selected 
patients with screening-detected Gleason score of 3＋4=7 
PCa, AS might be an option, especially in those with co-
morbidity or a short life expectancy [22]. Interestingly, the 
original Toronto cohort of AS included men with Gleason 
7 disease who were over 70, but the protocol was amended 
to only accept men with Gleason 6 [18].
OUTCOMES OF ACTIVE SURVEILLANCE
A pooled analysis by Chodak et al of original data from 828 
patients treated by the more traditional watchful waiting 
with intervention with metastatic disease as described ear-
lier was the catalyst for current AS strategies [23]. The 
pooled data were based on patients from six nonrandomized 
studies in which cancer-specific survival and meta-
stasis-free survival were reported with up to 10 years of fol-
low-up. Low- grade tumors did better than high-grade tu-
mors, with the prospect of metastasis development at 10 
years being approximately twice as great in the low-grade 
groups as in the high-grade groups. This also translated in-
to poorer survival for the higher risk tumors.
　The largest prospective series of modern AS from Toronto 
pioneered by Klotz et al has recently reported the outcome 
of AS with selective delayed intervention by using clinical 
PSA or histologic progression as treatment indications for 
clinically localized PCa [18]. With a median follow-up of 
around 8 years (range, 1-15 years), the total of 453 men rep-
resents the largest AS cohort in a prospective, single-arm, 
cohort study. Definitive intervention was offered to those 
patients with a PSA doubling time of less than 3 years, 
Gleason score progression (≥4＋3), or unequivocal clinical 
progression. Overall survival was 79%. The 10-year PCa 
actuarial survival was 97%. Among the 30% of patients 
(n=117) who were reclassified as higher risk and who were 
treated, PSA failure was relatively common at 50% (13% 
of the total cohort). Interestingly, data from the Swedish 
section of the European Randomized Study of Screening for 
Prostate Cancer did not find differences in intermediate 
outcomes between immediate radical prostatectomy (RP) 
and delayed RP [24]. There were limited patient numbers 
available for analysis and of course the delayed RP group 
may have been subject to a selection bias. Overall, more 
prospective datas are required to resolve this issue. 
　Notably, in the Klotz series, a PSA doubling time of 3 
years or less was associated with an 8.5 times higher risk 
of biochemical failure after definitive treatment compared 
with a doubling time of ＞3 years [18]. However, this must 
be balanced against an observed low rate of PCa mortality 
because other-cause mortality accounted for almost all of 
the deaths. Certainly, the conclusion that additional stud-
ies are warranted to improve the identification of patients 
who harbor more aggressive disease despite favorable clin-
ical parameters at diagnosis remains valid. Other robust- 
sized AS cohorts led by Carter et al [20] at Johns Hopkins 
and Dall’Era [25] at the University of California at San 
Francisco, both in the United States, are not mature 
enough yet but in the future may provide the supportive 
data necessary to help to refine selection and interven-
tional criteria.
TRIGGERS OR CRITERIA FOR INTERVENTION IN 
MEN UNDERGOING ACTIVE SURVEILLANCE 
Again, as with the selection criteria for AS, the triggers for 
leaving surveillance and having radical therapy are not 
well defined. Klotz focused on PSA kinetics [18], whereby 
a doubling time of less than 3 years is of concern, although 
this is only likely to happen in around a quarter of men in 
a large series. Others have elected to follow more regular 
biopsies, whereas others still believe that the criteria that 
patients were entered upon should be deemed exit points 
even after multiple biopsies [20,25]. What most agree on 
at this stage is that a combination of regular DRE, PSA, and 
biopsies at least between one and three yearly should all 
be factored into the decision to progress to radical therapy 
in the hope of obtaining a cure in men who were initially 
believed to have low-risk disease. Increasingly, dynamic 
contrast-enhanced and diffusion-weighted MRI is being 
incorporated into the algorithm to enhance the identi-
fication of men with large volume, usually anterior disease. 
This is particularly useful in patients with minimal 
Gleason 6 disease on biopsy and adverse PSA kinetics. 
IMAGING AND BIOMARKERS IN ACTIVE 
SURVEILLANCE
Useful adjuncts to current selection criteria are imaging 
and biomarkers. MRI is emerging as a useful tool [26]. The 
key features of MRI are that it is noninvasive, may differ-
entiate low-grade and high-grade PCa, and has much more 
sensitivity for large volume, clinically significant cancers 
[27]. Many candidates for AS will have tumor volumes well 
below 0.5 cc. A ‘negative’ MRI in a patient whose biopsy 
shows minimal disease therefore increases the likelihood 
that the patient does not harbor a significant volume of 
disease. MRI will have an increasing a role in selecting pa-
tients for AS and as a trigger for re-biopsy or intervention 
during surveillance. A particular group that may benefit 
are those who exhibit adverse PSA kinetics in the absence 
of benign prostatic hyperplasia (BPH) or inflammation, 
with minimal disease on repeat biopsy. Recent datas in-
dicate that current biopsy schemes often miss large-vol-
ume anterior tumors. This has been termed the pro-
static-evasive anterior tumor syndrome, or PEATS [28]. Korean J Urol 2010;51:665-670
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TABLE 2. Active surveillance: suggested algorithm for eligibility 
and follow-up
a
Eligibility
  - PSA ≤10 ng/ml
  - Gleason ≤6
  - T1c-T2a
  - Depending on age and comorbidity: ＜3 cores involved, ＜50%
of any one core
Follow-up schedule
  - PSA, digital rectal examination every 3 mo for 2 yr, then every
6 mo assuming PSA is stable
  - 10-12 core biopsy at 1 yr and then every 3 yr until age 80
  - Optional: Transrectal ultrasound on alternate visits
Triggers for Intervention
  - For PSA doubling time of ＜3 yr (in most cases, based on at least
8 determinations; about 20% of patients)
  - For grade progression to Gleason 7 (4 ＋  3) or higher (about 5%
of patients)
PSA: prostate-specific antigen, 
a: adapted from Klotz and Nam [2].
These are guidelines and should be modified according to patient
age and comorbidity.
MRI may help to uncover such patients and direct further 
biopsies. A current challenge is to better understand MRI 
images in men considering or being managed with AS. This 
requires the pooling of data from individual patients’ tu-
mors with the combination of different sequences, use of 
diffusion-weighted MRI (DW-MRI), magnetic resonance 
spectroscopy, and other contrast manipulations combined 
with biopsy data [29]. The idea that men on AS could have 
cancer volume progression and tumor grade documented 
with MRI is enticing [26].
　Many disease biomarkers are currently being evaluated. 
These include multiparametric tissue-based assays using 
a systems pathology approach (i.e., the Aureon test), mi-
tochondrial deletion assays (Mitomics), somatic cell SNP 
analysis, and the PCa antigen 3 (PCA3) urine-based assay. 
The PCA3 test may allow prebiopsy risk stratification. 
PCA3-based nomograms have been applied and validated 
in a large, external, European cohort of men at risk of PCa 
[30], which adds data to the data already published in the 
United States [31]. A biomarker assay that accurately pre-
dicts tumor aggressivity (or benignity) would enhance pa-
tient selection, PCA3 follow-up, timing, and need for biop-
sies in AS protocols. Although the conventional PSA and 
biopsy based approach to surveillance is associated with an 
extremely low PCa mortality rate, approximately one third 
of patients are eventually subjected to radical therapy. The 
benefit of the imaging and biomarker enhanced approach 
would be to lower the proportion of patients on surveillance 
requiring definitive intervention and to generate an earlier 
signal for intervention in the remaining minority who are 
reclassified as higher risk. Ultimately, biomarkers and 
imaging may be combined together to create individualized 
and tailored ‘biological signatures.’ 
MORTALITY FROM ACTIVE SURVEILLANCE
Currently, there are few datas regarding mortality from 
AS. The reported data for patients dying while on active 
surveillance is best addressed by the University of Toronto 
cohort. Krakowsky et al reported that out of a series of 
around 450 patients on AS, 5 died of PCa [32]. All of them 
had a PSA doubling time of 1.6 years or less, thus triggering 
a recommendation for radical therapy. Radical intervention 
was performed in three of the five patients. Two received 
radiation and one underwent radical prostatectomy. Of the 
2 patients who did not receive definitive treatment, one was 
lost to follow-up and was treated conservatively by his fam-
ily doctor, whereas the other elected androgen-deprivation 
therapy rather than radical treatment. Overall, there was 
a low cancer-specific mortality in this, thus providing sup-
port for an AS approach to favorable-risk PCa. This is nota-
ble because only 1 of the 453 patients presented with favor-
able disease had a time course of disease progression that 
left open the possibility that he might have suffered a pre-
ventable death. This analysis reinforces the importance of 
close monitoring and of definitive treatment for those in 
whom disease is reclassified as higher risk over time.
ACTIVE SURVEILLANCE IN ASIAN MEN
This was a retrospective study of 131 Korean men who un-
derwent RP for clinically insignificant PCa as defined by 
contemporary Epstein criteria as unfavorable PCa (patho-
logical Gleason sum ＞7 and/or extraprostatic extension) 
[17]. Their results showed that a significant proportion of 
contemporary Korean patients who meet all the conditions 
of the contemporary Epstein criteria for prediction of clin-
ically insignificant PCa might actually harbor cancer with 
unfavorable pathological features. The large Japanese 
multicenter study by Kakehi et al demonstrated a patho-
logical progression rate at 1-year re-biopsy of 33% [21]. 
However, almost half of the patients remained on AS for 
a maximal observation period of 54 months, thus giving cre-
dence to AS in Asian men. Given the low mortality from PCa 
in Asian men compared with Western men, AS is even more 
appealing in Asians, not withstanding the results of this 
small trial. 
THE FUTURE OF ACTIVE SURVEILLANCE
AS is increasingly becoming popular as a strategy for se-
lected men in Europe, Canada, and Australia, with the 
United States tentatively following. Suggested eligibility 
criteria, follow-up schedule, and triggers for intervention 
are summarized on the basis of current knowledge (Table 
2). However, the future of AS and uptake as a modality to 
manage low-risk PCa will depend on better patient se-
lection and improved identification of when the disease 
process has altered such that radical intervention is re-
quired prior to local advancement or metastases. On the 
first point, the two most likely candidates for achieving this 
are imaging, particularly with MRI and biomarkers.Korean J Urol 2010;51:665-670
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　Regarding the ability to better identify those at risk of 
progression while on AS, the tools available are PSA and 
PSA velocity, DRE, repeat biopsy, and serial imaging. Most 
of these tools are currently used in AS protocols. Imaging 
has been used where discordance between PSA and other 
biopsy findings exists with anteriorly placed tumors using 
MRI [28]. Biomarkers for this indication are in develop-
ment. 
　Another major development may be data supporting the 
use of 5-alpha reductase inhibitors (5ARIs) in the AS 
setting. Two large trials, PCPT [33] and REDUCE [34], 
have reported that the rate of PCa diagnosis is decreased 
by 30% with 5ARIs. Many men in these studies harbored 
undiagnosed PCa at entry. Thus, it is a reasonable in-
ference that these drugs act to stabilize or reduce the vol-
ume of existing PCa; indeed, that may be their main mode 
of action as prevention agents. One study testing this hy-
pothesis in surveillance patients, the REDEEM study [35], 
has been completed but has not yet reported. It is possible 
that for many men with favorable-risk PCa, a 5ARI repre-
sents a low-cost, minimal intervention that is sufficient to 
further reduce their risk of progression to exceedingly low 
levels. At this point, however, there is no direct evidence 
to support this hypothesis. While placing men on surveil-
lance on 5ARIs is appealing, particularly if they have other 
indications for the drug (i.e., BPH symptoms), it should not 
be considered a definitive therapy. Such patients still re-
quire close monitoring and periodic biopsies. The PSA ki-
netics in men on 5ARI are simply recalibrated from the new 
baseline nadir.
　A large randomized controlled trial comparing standard 
treatment with surgery or radiation against active surveil-
lance, or the Surveillance Therapy Against Radical Treat-
ment (START) trial, is currently recruiting and will answer 
the question of which management strategy is best for pa-
tients with low-risk PCa [36]. The PROTECT study of AS, 
radical prostatectomy, or radiation therapy for localized 
PCa from the United Kingdom [37] and the European-based 
large, prospective, observational AS registry known as the 
Prostate Cancer Research International: Active Survei-
llance (PRIAS) study will both add much needed data to 
help urologists and patients decide on the best manage-
ment strategy for low-risk PCa [38].
　AS is an appealing option for men with favorable-risk 
PCa, particularly those whose extent of disease appears 
minimal. It has been demonstrated to be safe in the inter-
mediate time frame. The quality of life benefits are 
indisputable. The controversy in this field is now related 
to optimal patient selection and the ideal triggers for 
intervention. 
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